Dental

Nov 19 2019

Gsk stock price




Gsk stock price-Gsk stock price
Gsk stock price-GSK | A complete GSK overview by MarketWatch. View the latest market news and prices, and trading information.

GlaxoSmithKline PLC ADR

Close Chg Chg %
$42.34 0.30 0.71% 0.30 0.71%

Your Watchlist

Customize MarketWatch

Have Watchlists? Log in to see them here or sign up to get started.

No Items in Watchlist

There are currently no items in this Watchlist.

No Saved Watchlists

Create a list of the investments you want to track.

Something went wrong while loading Watchlist.

Recently Viewed Tickers

No Recent Tickers

Visit a quote page and your recently viewed tickers will be displayed here.

  • Open $42.39
  • Day Range 42.15 – 42.52
  • 52 Week Range 36.41 – 42.64
  • Market Cap $96.42B
  • Shares Outstanding 2.49B
  • Public Float 2.28B
  • Beta 0.63
  • Rev. per Employee $430.38K
  • P/E Ratio 18.39
  • EPS $2.30
  • Yield 4.71%
  • Div >$0.46
  • Ex-Div >Aug 8, 2019
  • Short Interest 6.56M 09/13/19
  • % of Float Shorted 0.29%
  • Average Volume 2.33M

Performance

5 Day
  • 1.71%
1 Month
  • 1.83%
3 Month
  • 5.80%
YTD
  • 10.81%
1 Year
  • 5.40%

Recent News

  • MarketWatch
  • WSJ

Clovis Oncology Falls After Analyst Blasts New Licensing Deal

SVB Leerink analyst Andrew Berens said the company’s decision to license a targeted radiotherapy program from a private German biotechnology company was ill timed.

  • Sep. 24, 2019 at 8:58 a.m. ET
  • by Barron’s

Amid rising reports of a vaping-related lung illness, here’s how to kick your e-cigarette addiction

  • Sep. 6, 2019 at 2:41 p.m. ET
  • by Meera Jagannathan

The Dow Is Up 95 Points Because the Jobs Report Could Have Been Worse

Fewer people than expected were hired in August, but the share of Americans with a job increased and wage growth strengthened.

  • Sep. 6, 2019 at 12:57 p.m. ET
  • by Barron’s

Podcast: Biotech’s Big >Host Alex Eule is joined by Josh Nathan-Kasiz to talk about one of biotech’s most promising treatments, mRNA therapy.

  • Sep. 5, 2019 at 12:52 p.m. ET
  • by Barron’s

How to Invest in MRNA Technology

Patience–and taking cues from the big pharmaceutical companies–are the keys to making this biotech bet

  • Aug. 30, 2019 at 6:59 p.m. ET
  • by Barron’s

The Next Frontier in Treating Disease

Biotechnology companies are working to develop cutting-edge drugs out of messenger RNA, hoping the technology will be able to deliver the benefits of targeted gene therapy with less risk.

  • Aug. 30, 2019 at 6:57 p.m. ET
  • by Barron’s

GlaxoSmithKline ViiV reports positive HIV study

GlaxoSmithKline PLC’s (GSK.LN) joint-venture company ViiV Healthcare said Thursday that a global phase 3 “Atlas-2M” study of rilpivirine for the treatment of HIV met its primary endpoint. ViiV Healthcare–which is jointly owned by Pfizer Inc. (PFE) — said the study showed a combination of cabotegravir and rilpivirine administered every eight weeks is similar to a four-week administration.

  • Aug. 22, 2019 at 3:21 a.m. ET

GlaxoSmithKline’s revenue boosted by vaccines

LONDON — GlaxoSmithKline PLC said newer vaccines and a tax windfall softened the bite of competition from a new generic version of its best-selling inhaler Advair in the second quarter. The British health care giant said Wednesday that revenue rose 5% at constant currencies to GBP7.8 billion in the three months to June 30, largely thanks to strong sales of shingles vaccine Shingrix.

  • Jul. 24, 2019 at 9:30 a.m. ET

GlaxoSmithKline says Symonds will become chairman

Pharmaceutical giant GlaxoSmithKline said Wednesday that Jonathan Symonds will succeed Phillip Hampton as non-executive chairman. Symonds, who will take on the role on Sept. 1, is currently deputy chairman for HSBC Holdings and a former chief financial officer of rival drugmakers Novartis and AstraZeneca .

  • Jul. 24, 2019 at 5:05 a.m. ET
  • by Steve Goldstein

23andMe and GSK are mining customers’ DNA data in a hunt for new drugs

  • Jul. 23, 2019 at 7:51 a.m. ET
  • by Denise Roland

Chipotle, Boeing, Tesla and More Stocks to Watch This Week

A flurry of earnings reports this week from Facebook, Coca-Cola, Caterpillar and many more. Investors will also see economic data on gross domestic product, the housing market, and durable goods.

  • Jul. 22, 2019 at 8:00 a.m. ET
  • by Barron’s

Disney’s Box-Office Formula: Big-Budget Sequels and Reboots

The strategy works wonders, producing nearly 20% of worldwide box office last year. And this weekend comes the latest: the live-action remake of “The Lion King.”

]]>

Gsk stock price

SOURCE: http://www.marketwatch.com/investing/stock/GSK


Written by admin


Leave a Reply

Your email address will not be published. Required fields are marked *